| Literature DB >> 31299899 |
Kifaya Azmi1,2,3, Walaa Qrei4, Ziad Abdeen4,5.
Abstract
BACKGROUND: Intercellular adhesion and biofilm production by Staphylococcus aureus makes these bacteria resistant to antimicrobial therapy. Here, Methicillin-resistant Staphylococcus aureus (MRSA) strains were characterized and the prevalence of genes encoding adhesion factors and biofilm formation was determined.Entities:
Keywords: Agr; Antibiotics; Biofilm; MRSA; SCCmec; sarA
Year: 2019 PMID: 31299899 PMCID: PMC6624993 DOI: 10.1186/s12864-019-5929-1
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Frequency of antibiotic resistance of MRSA strains and biofilm
| Antibiotics | Weak biofilm producer (0.07 < ODs ≤ 0.14) | Moderate biofilm producer (0.14 < ODs ≤ 0.28) | Strong biofilm producer (0.28 < ODs) | Total ( | ||||
|---|---|---|---|---|---|---|---|---|
| S n. (%) | R n. (%) | S n. (%) | R n. (%) | S n. (%) | R n. (%) | S n. (%) | R n. (%) | |
| Cefoxitin | 0 (0%) | 81 (32.7) | 0 (0) | 115 (46.3) | 0 (0) | 52 (20.9) | 0 (0) | 248 (100) |
| Penicillin | 0 (0%) | 81 (32.6) | 0 (0) | 115 (46.3) | 0 (0) | 52 (20.9) | 0 (0) | 248 (100) |
| Ciprofloxacin | 49 (19.8%) | 32 (12.9) | 69 (27.8) | 45 (18.1) | 19 (7.6) | 32 (12.9) | 137 (55.2) | 109 (43.9) |
| Clindamycin | 50 (20.2%) | 31 (12.5) | 75 (30.2) | 40 (16.1) | 28 (11.2) | 24 (9.7) | 153 (61.6) | 95 (38.3) |
| Erythromycin | 29 (11.7%) | 52 (20.9) | 36 (14.5) | 79 (31.8) | 20 (8.0) | 32 (12.9) | 85 (34.2) | 163 (65.7) |
| Gentamycin | 69 (27.8%) | 12 (4.8) | 93 (37.5) | 22 (8.8) | 28 (11.2) | 24 (9.6) | 190 (76.6) | 58 (23.3) |
| SXT | 65 (26.2%) | 16 (6.4) | 92 (37.1) | 23 (9.2) | 36 (14.5) | 16 (6.4) | 193 (77.8) | 55 (22.1) |
| Vancomycin | 81 (32.7%) | 0 (0) | 115 (46.3) | 0 (0) | 52 (20.9) | 0 (0) | 248 (100) | 0 (0) |
The presence of biofilm-related genes for each agr group
| Agr group (%) | ||||||
|---|---|---|---|---|---|---|
| Biofilm Plate Titer (N = 248) | AgrI | AgrII | AgrIII | AgrIV | NT | SarA gene |
| Weak biofilm producer ( | 30.6 | 17.4 | 43.9 | 66.7 | 13.9 | 77.7 |
| Modertae biofilm producer ( | 42.9 | 56.5 | 50.0 | 22.2 | 47.2 | 73.9 |
| Strong biofilm producer ( | 26.5 | 26.1 | 6.1 | 11.1 | 38.9 | 48.1 |
| Total (n, %) | (98, 39.5%) | (23, 9.3%) | (82, 33.1%) | (9, 3.6%) | (36, 14.5%) | 173 |
| | 80.6 | 65.2 | 80.5 | 77.7 | 16.6 | |
| Adhesion Genes | ||||||
| icaD/ icaA(n = 248) | 87.7 | 87.0 | 78.0 | 88.9 | 80.6 | 58.5 |
| Eno ( | 92.9 | 91.3 | 97.6 | 100.0 | 94.4 | 71.5 |
| ClfA ( | 92.9 | 87.0 | 89.0 | 55.6 | 27.8 | 80.4 |
| ClfB (n = 199, 80.2%) | 92.9 | 87.0 | 89.0 | 55.6 | 27.8 | 80.4 |
| FnbA ( | 87.8 | 78.3 | 91.5 | 66.7 | 25.0 | 81.4 |
| EbpS ( | 82.7 | 60.9 | 84.1 | 55.6 | 55.6 | 76.4 |
| Fib ( | 60.2 | 73.9 | 80.5 | 66.7 | 16.7 | 83.1 |
| Cna ( | 46.9 | 21.7 | 53.7 | 0.0 | 11.1 | 78.8 |
| FnbB ( | 52.0 | 21.7 | 13.4 | 11.1 | 11.1 | 81.9 |
| Antibiotic Resistance | ||||||
| Cefoxitin/Penicillin (n = 248) | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100 |
| Erythromycin ( | 59.2 | 60.9 | 69.5 | 33.3 | 86.1 | 63.2 |
| Ciprofloxacin ( | 58.2 | 56.5 | 20.7 | 33.3 | 52.8 | 63.3 |
| Clindamycin ( | 28.6 | 43.5 | 48.8 | 11.1 | 44.4 | 65.3 |
| Gentamycin ( | 27.6 | 21.7 | 11.0 | 22.2 | 41.7 | 55.2 |
| SXT ( | 19.4 | 21.7 | 11.0 | 11.1 | 58.3 | 41.8 |
| MDR ( | 22.4 | 43.5 | 13.4 | 11.1 | 61.1 | 46.9 |
| Source of isolate | ||||||
| Wound ( | 36.7 | 34.8 | 35.4 | 22.2 | 8.3 | 80.7 |
| Blood ( | 11.2 | 17.4 | 11.0 | 11.1 | 25.0 | 52.9 |
| Nasal ( | 11.2 | 13.0 | 8.5 | 0.0 | 11.1 | 64 |
| Pus (n = 23) | 8.2 | 8.7 | 13.4 | 22.2 | 0.0 | 95.6 |
| Urine (n = 23) | 1.0 | 0.0 | 11.0 | 22.2 | 30.6 | 43.5 |
| Tissue ( | 9.2 | 8.7 | 2.4 | 0.0 | 0.0 | 61.5 |
| Sputum ( | 3.1 | 8.7 | 6.1 | 0.0 | 5.6 | 58.3 |
| Other sites ( | 19.4 | 8.7 | 12.2 | 22.2 | 19.4 | 72.5 |
Biofilm-forming capacity of 248 methicillin-resistant strains of Staphylococcus aureus (MRSA) and percentages of their adhesion genes related to antibiotics
| Biofilm | Adhesion gene | Gentamycin % | Ciprofloaxin % | SXT % | Erythromycin % | Clindamycin % | MDR % | Total % |
|---|---|---|---|---|---|---|---|---|
| Strong (n = 52, 20.9%) | FinbB | 23.1 | 23.1 | 1.9 | 15.4 | 11.5 | 7.7 | 46.2 |
| ClfA/ClfB | 32.7 | 40.4 | 11.5 | 36.5 | 28.8 | 19.2 | 69.2 | |
| Ebps | 42.3 | 46.2 | 21.2 | 44.2 | 34.6 | 32.7 | 71.2 | |
| Can | 15.4 | 19.2 | 3.8 | 15.4 | 11.5 | 7.7 | 38.5 | |
| Eno | 46.2 | 59.6 | 30.8 | 57.7 | 25.0 | 38.5 | 94.2 | |
| Icad | 42.3 | 57.7 | 26.9 | 51.9 | 36.5 | 32.7 | 88.5 | |
| FinbA | 34.6 | 44.2 | 13.5 | 38.5 | 26.9 | 21.2 | 71.2 | |
| Fib | 26.9 | 34.6 | 5.8 | 28.8 | 21.2 | 17.3 | 46.2 | |
| Moderate (n = 115, 46.3%) | FinbB | 5.2 | 18.3 | 0.9 | 17.4 | 6.1 | 6.1 | 26.1 |
| ClfA/ClfB | 13.0 | 30.4 | 13.0 | 54.8 | 28.7 | 17.4 | 81.7 | |
| Ebps | 12.2 | 31.3 | 13.9 | 53.0 | 27.0 | 18.3 | 79.1 | |
| Can | 7.0 | 7.8 | 8.7 | 28.7 | 17.4 | 8.7 | 40.9 | |
| Eno | 18.3 | 36.5 | 19.1 | 65.2 | 33.0 | 26.1 | 94.8 | |
| Icad | 13.9 | 32.2 | 17.4 | 56.5 | 29.6 | 21.7 | 82.6 | |
| FinbA | 9.6 | 28.7 | 9.6 | 50.4 | 24.3 | 12.2 | 78.3 | |
| Fib | 7.8 | 26.1 | 7.0 | 43.5 | 22.6 | 10.4 | 64.3 | |
| Weak (n = 81, 32.6%) | FinbB | 3.7 | 14.8 | 7.4 | 24.7 | 8.6 | 6.2 | 88.9 |
| ClfA/ClfB | 13.6 | 34.6 | 66.7 | 51.9 | 33.3 | 17.3 | 82.7 | |
| CLFB | 13.6 | 34.6 | 17.3 | 54.3 | 33.3 | 17.3 | 86.4 | |
| Ebps | 11.1 | 30.9 | 14.8 | 46.9 | 30.9 | 14.8 | 75.3 | |
| Can | 7.4 | 11.1 | 7.4 | 23.5 | 17.3 | 7.4 | 39.5 | |
| Eno | 12.3 | 37.0 | 17.3 | 59.3 | 37.0 | 17.3 | 95.1 | |
| Icad | 12.3 | 30.9 | 14.8 | 51.9 | 33.3 | 18.5 | 81.5 | |
| FinbA | 13.6 | 30.9 | 14.8 | 51.9 | 33.3 | 17.3 | 82.7 | |
| Fib | 9.9 | 29.6 | 8.6 | 45.7 | 28.4 | 11.1 | 69.1 |
Fig. 1Biofilm phenotype and the source of strains of MRSA, i. e. tissues and lesions